Related Experiment Videos
Anti-inflammatory constituents from Tabebuia avellanedae
Maorong Suo1, Hasegawa Isao, Hikaru Kato
1Department of Pharmacognosy and Chemistry of Natural Products, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. suomaorong@163.com
Fitoterapia
|September 8, 2012
Summary
Five new compounds from Tabebuia avellanedae inhibit inflammatory cytokines tumor-necrosis factor-alpha and interleukin-1beta. These compounds also demonstrated anti-allergic and antioxidant properties without significant toxicity.
Area of Science:
- Natural Product Chemistry
- Pharmacology
- Immunology
Background:
- Tabebuia avellanedae is a plant with potential medicinal properties.
- Inflammatory cytokines like TNF-α and IL-1β play crucial roles in immune responses and diseases.
- Developing new therapeutic agents for inflammatory and allergic conditions is a significant area of research.
Purpose of the Study:
- To isolate and characterize novel compounds from Tabebuia avellanedae.
- To evaluate the inhibitory effects of these compounds on inflammatory cytokine production.
- To assess the anti-allergic and antioxidant activities of the isolated compounds.
Main Methods:
- Isolation of five novel compounds using phytochemical techniques.
- Structure elucidation of compounds 1-5 via NMR spectroscopy and mass spectrometry.
- In vitro assays using cultured human myeloma THP-1 cells to measure cytokine inhibition, cytotoxicity, anti-allergic, and antioxidant activities.
Main Results:
- Five novel compounds were successfully isolated and structurally identified.
- Compounds 1-5 exhibited significant inhibition of tumor-necrosis factor-α and interleukin-1β production at 25μM.
- No significant cytotoxicity was observed for the tested compounds.
- Preliminary evaluation of anti-allergic and antioxidant activities was performed.
Conclusions:
- Tabebuia avellanedae is a source of novel bioactive compounds.
- The isolated compounds possess potent anti-inflammatory properties by inhibiting key cytokines.
- These compounds represent potential candidates for the development of new treatments for inflammatory and allergic diseases.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:24Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.